Asthma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators), By Product (Inhalers (Dry powder inhalers, Metered dose inhalers, Soft mist inhalers), Nebulizers), By Route of Administration (Oral, Inhaled, Others), By Region and Competition, 2019-2029F
Global Asthma Therapeutics Market was valued at USD 23.52 Billion in 2023 and is anticipated t%li%project steady growth in the forecast period with a CAGR of 3.25% through 2029. Asthma remains a significant global health concern, affecting millions of individuals worldwide and posing challenges for healthcare systems across the globe. With its prevalence steadily increasing, the global asthma therapeutics market has been evolving rapidly t%li%meet the needs of patients and healthcare providers. Characterized by airway inflammation and constriction, asthma manifests through various symptoms such as wheezing, shortness of breath, coughing, and chest tightness.
Inhaled corticosteroids, leukotriene modifiers, and long-acting beta-agonists are among the commonly prescribed medications for asthma management. These medications help alleviate symptoms and prevent exacerbations by targeting underlying inflammation and bronchial constriction. Additionally, short-acting beta-agonists such as albuterol are often used for immediate symptom relief during acute asthma attacks, providing rapid bronchodilation t%li%improve airflow and alleviate symptoms. The global asthma therapeutics market is poised for further evolution and improvement in asthma management. Innovations in drug development, including the introduction of new biologics and other novel therapies, hold promise for providing additional treatment options for patients with severe and uncontrolled asthma. Biologics, in particular, target specific pathways involved in asthma pathogenesis, offering personalized treatment approaches tailored t%li%individual patient needs. These advancements in treatment modalities have the potential t%li%revolutionize asthma management, offering better outcomes and improved quality of life for patients.
Ongoing research int%li%the genetic and molecular basis of asthma is expected t%li%drive personalized treatment strategies and enhance our understanding of the disease. By identifying genetic markers and molecular pathways associated with asthma susceptibility and severity, researchers aim t%li%develop targeted therapies that address the underlying mechanisms driving the disease. Personalized treatment plans based on genetic profiling and biomarker analysis could enable healthcare providers t%li%tailor therapies t%li%individual patient profiles, optimizing treatment outcomes and minimizing adverse effects. The global asthma therapeutics market continues t%li%evolve in response t%li%the growing burden of asthma worldwide. Advances in medical research, drug development, and personalized medicine offer new hope for patients with asthma, providing a range of treatment options and improving overall asthma management. By leveraging innovative therapies and personalized treatment approaches, healthcare providers can better meet the needs of patients with asthma, reducing symptom burden, preventing exacerbations, and improving quality of life.
Key Market Drivers
Rising Prevalence of Asthma
Asthma is a global health concern, affecting people of all ages, from children t%li%the elderly. The burden of asthma is not just limited t%li%its prevalence but extends t%li%its impact on patients' lives and healthcare costs. Several factors contribute t%li%the increasing prevalence of asthma. Exposure t%li%various environmental triggers such as allergens, air pollution, and tobacc%li%smoke can increase the risk of asthma. Urbanization and industrialization have led t%li%increased exposure t%li%these triggers in many parts of the world. A family history of asthma or allergic conditions can predispose individuals t%li%the development of asthma. Genetic factors play a significant role in susceptibility t%li%the disease.
Sedentary lifestyles, changes in dietary habits, and increased stress levels have been linked t%li%the rising prevalence of asthma. These factors can lead t%li%obesity, which is a known risk factor for asthma. Improved diagnostic methods and increased awareness about asthma have led t%li%more individuals seeking medical help, resulting in a higher number of reported cases. As the global population continues t%li%age, the prevalence of chronic diseases like asthma als%li%increases, as the condition is not limited t%li%any specific age group. Developing countries are witnessing a rise in asthma cases due t%li%urbanization and industrial growth, leading t%li%increased exposure t%li%asthma triggers. The increasing prevalence of asthma has driven the growth of the global asthma therapeutics market. Pharmaceutical companies have been investing in research and development t%li%create more effective treatments for asthma. The market includes a wide range of therapeutics, including inhaled corticosteroids, long-acting beta-agonists, leukotriene modifiers, and monoclonal antibodies, among others.
Increasing Healthcare Expenditure
Asthma is a chronic respiratory condition that affects millions of people worldwide. With a rising prevalence of asthma and an increasing focus on healthcare, the global asthma therapeutics market is experiencing significant growth. One of the primary drivers of this growth is the increasing healthcare expenditure in various countries. As governments and healthcare organizations recognize the growing burden of chronic diseases like asthma, they are allocating larger budgets t%li%healthcare. Increased healthcare expenditure is enabling better access t%li%healthcare services, including improved diagnosis and management of asthma. These investments have a direct impact on the asthma therapeutics market, driving its growth. Asthma therapeutics have come a long way in recent years, thanks t%li%advancements in medical research and technology. Pharmaceutical companies are investing heavily in the development of innovative drugs and therapies t%li%improve asthma management. With greater healthcare spending, more resources are available for research and development, leading t%li%the creation of more effective and efficient asthma treatments.
In many countries, the accessibility of asthma medications has improved significantly due t%li%increased healthcare expenditure. This means that patients have better access t%li%a wide range of asthma therapeutics, from quick-relief inhalers t%li%long-term control medications. This improved access ensures that patients can manage their condition effectively, leading t%li%better health outcomes. Higher healthcare spending als%li%allows for increased asthma awareness campaigns and patient education programs. When patients are well-informed about their condition and treatment options, they are more likely t%li%adhere t%li%their treatment plans. This ultimately leads t%li%better control of asthma, reducing the severity and frequency of symptoms and hospital admissions.
Research and development in the asthma therapeutics market are heavily influenced by healthcare expenditure. Greater financial support for research activities results in the discovery of new drugs and therapies that can revolutionize asthma management. These advancements benefit both patients and the pharmaceutical industry, as they create a more competitive and dynamic market. The global asthma therapeutics market is expanding as healthcare expenditure rises. In addition t%li%the core treatment options, there is a growing interest in personalized medicine and biologics in the treatment of asthma. These innovative approaches offer a promising future for patients with severe or difficult-to-treat asthma.
While increasing healthcare expenditure is driving growth in the asthma therapeutics market, there are some challenges t%li%address. Balancing the need for better treatments with the rising cost of healthcare is a delicate task. It's essential t%li%ensure that healthcare resources are utilized efficiently and that affordable treatment options are available t%li%all, regardless of socioeconomic status.
Key Market Challenges
Generic Competition
The patent expirations of several blockbuster asthma drugs have led t%li%increased competition from generic alternatives. While this can drive down prices, it can als%li%pose a challenge for pharmaceutical companies and innovators in terms of sustaining profitability and investing in research and development for new, innovative therapies. Asthma is a heterogeneous disease with various phenotypes and endotypes. Developing therapeutics that cater t%li%the diverse needs of patients is a complex task. Tailoring treatments t%li%individual asthma subtypes is challenging, as it requires a deep understanding of the underlying mechanisms and can be costly. Asthma management relies on long-term adherence t%li%medication regimens. However, many patients struggle with non-adherence, whether due t%li%inconvenience, side effects, or lack of understanding of the importance of consistent treatment. This can hinder the effectiveness of asthma therapeutics and result in uncontrolled asthma.
Key Market Trends
Technological Advancements
Asthma is a chronic respiratory condition that affects millions of people worldwide, causing symptoms such as wheezing, shortness of breath, and coughing. With the increasing prevalence of asthma cases globally, the demand for effective and innovative asthma therapeutics is on the rise. Technological advancements have played a pivotal role in the development of new and improved treatments, leading t%li%a booming Global Asthma Therapeutics Market. Technological innovations have led t%li%more accurate and efficient methods for diagnosing asthma. Traditional diagnostic methods, such as spirometry and peak flow measurements, have been supplemented with advanced diagnostic tools like exhaled nitric oxide (FeNO) testing and fractional exhaled nitric oxide (FeNO) monitors. These tools offer better insights int%li%airway inflammation, aiding in more precise asthma diagnosis. Telemedicine has revolutionized the healthcare industry, providing convenient access t%li%healthcare professionals and specialists. Remote monitoring devices, including smart inhalers and wearable sensors, allow patients and doctors t%li%track asthma symptoms and medication adherence. This real-time data helps in creating personalized treatment plans and ensures better management of the condition.
Advancements in genetic research and personalized medicine have allowed for the development of targeted asthma treatments. By identifying specific genetic markers associated with asthma, pharmaceutical companies can create therapies tailored t%li%an individual's unique genetic profile. This approach leads t%li%more effective treatments and fewer side effects. Biologics, a class of medications derived from living organisms, have emerged as a groundbreaking treatment for severe asthma. These drugs target specific molecules in the immune system, effectively reducing inflammation and preventing asthma exacerbations. Monoclonal antibodies, a type of biologic, are increasingly used t%li%treat severe asthma, offering hope t%li%patients wh%li%d%li%not respond well t%li%traditional therapies. Inhalers have come a long way with technological advancements. Smart inhalers, equipped with Bluetooth connectivity and companion mobile apps, help patients track their inhaler usage, monitor medication adherence, and receive reminders for inhalation. These innovations enhance patient engagement and contribute t%li%better asthma management.
AI and machine learning are invaluable tools in asthma research. They analyze vast amounts of patient data, identify patterns, and predict asthma exacerbations. Researchers use AI t%li%develop predictive models that can guide treatment decisions and improve patient outcomes. Advanced computational modeling and virtual screening techniques are accelerating the drug discovery process. These technologies help identify potential asthma therapies faster, reducing the time and costs associated with bringing new medications t%li%market. As a result, the pipeline for asthma drug candidates is growing rapidly.
Segmental Insights
Drug Class Insights
Based on drug class, Combination Therapy emerged as the fastest growing segment in the global market for asthma therapeutics in 2023. Combination therapy can provide better symptom control by addressing multiple aspects of asthma simultaneously. By combining a long-acting beta-agonist (LABA) with an ICS, for instance, patients can experience improved lung function, reduced inflammation, and fewer exacerbations. Asthma is not a one-size-fits-all condition. Combination therapy allows for personalized treatment regimens that can be adjusted t%li%suit an individual's specific needs, considering factors like the severity of their asthma, their response t%li%different medications, and comorbid conditions. Traditional reliance on SABA medications may lead t%li%overuse and increased risk of side effects. Combination therapy can reduce the need for SABA, promoting safer, more effective asthma management. Asthma exacerbations can be severe and sometimes life-threatening. Combination therapy can significantly reduce the risk of exacerbations, leading t%li%better long-term outcomes for asthma patients. With the development of advanced inhaler devices, patients can now conveniently administer combination therapies, making them easier t%li%incorporate int%li%their daily routines.
Product Insights
Based on product, the inhalers is projected t%li%experience rapid growth in the global asthma therapeutics market during the forecast period. Inhalers deliver medication directly t%li%the airways, ensuring that the drugs act where they are needed most. This targeted delivery reduces the risk of systemic side effects and provides faster relief. Inhalers are user-friendly and offer an easy, convenient method of medication administration. This enhances patient compliance, as individuals are more likely t%li%adhere t%li%their prescribed treatment plans. Inhalers typically require lower medication doses compared t%li%oral medications. This can lead t%li%cost savings for patients and healthcare systems and decrease the potential for adverse reactions. Inhalers come in various types, including short-acting and long-acting bronchodilators, inhaled corticosteroids, and combination therapies. This allows healthcare providers t%li%tailor treatment regimens t%li%the individual needs of asthma patients.
Regional Insights
Based on region, North America emerged as the dominant region in the Global Asthma Therapeutics Market in 2023, holding the largest market share in terms of value. One of the primary reasons for North America's leading position in the global asthma therapeutics market is the high prevalence of asthma in the region. The United States, Canada, and Mexic%li%collectively have a substantial population suffering from asthma, which drives the demand for effective asthma treatments and medications. As a result, pharmaceutical companies are heavily invested in the North American market, leading t%li%a robust pipeline of asthma therapeutics. North America boasts a sophisticated healthcare infrastructure, characterized by state-of-the-art medical facilities, a well-trained healthcare workforce, and a strong emphasis on research and development. This conducive environment has allowed the region t%li%excel in asthma research, enabling the development of innovative therapies and treatments. The presence of top-tier research institutions and pharmaceutical companies in North America has further contributed t%li%the region's dominance in the asthma therapeutics market.
Key Market Players
In this report, the Global Asthma Therapeutics Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Asthma Therapeutics Market.
Available Customizations:
Global Asthma Therapeutics Market report with the given market data, Tech Sci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
Inhaled corticosteroids, leukotriene modifiers, and long-acting beta-agonists are among the commonly prescribed medications for asthma management. These medications help alleviate symptoms and prevent exacerbations by targeting underlying inflammation and bronchial constriction. Additionally, short-acting beta-agonists such as albuterol are often used for immediate symptom relief during acute asthma attacks, providing rapid bronchodilation t%li%improve airflow and alleviate symptoms. The global asthma therapeutics market is poised for further evolution and improvement in asthma management. Innovations in drug development, including the introduction of new biologics and other novel therapies, hold promise for providing additional treatment options for patients with severe and uncontrolled asthma. Biologics, in particular, target specific pathways involved in asthma pathogenesis, offering personalized treatment approaches tailored t%li%individual patient needs. These advancements in treatment modalities have the potential t%li%revolutionize asthma management, offering better outcomes and improved quality of life for patients.
Ongoing research int%li%the genetic and molecular basis of asthma is expected t%li%drive personalized treatment strategies and enhance our understanding of the disease. By identifying genetic markers and molecular pathways associated with asthma susceptibility and severity, researchers aim t%li%develop targeted therapies that address the underlying mechanisms driving the disease. Personalized treatment plans based on genetic profiling and biomarker analysis could enable healthcare providers t%li%tailor therapies t%li%individual patient profiles, optimizing treatment outcomes and minimizing adverse effects. The global asthma therapeutics market continues t%li%evolve in response t%li%the growing burden of asthma worldwide. Advances in medical research, drug development, and personalized medicine offer new hope for patients with asthma, providing a range of treatment options and improving overall asthma management. By leveraging innovative therapies and personalized treatment approaches, healthcare providers can better meet the needs of patients with asthma, reducing symptom burden, preventing exacerbations, and improving quality of life.
Key Market Drivers
Rising Prevalence of Asthma
Asthma is a global health concern, affecting people of all ages, from children t%li%the elderly. The burden of asthma is not just limited t%li%its prevalence but extends t%li%its impact on patients' lives and healthcare costs. Several factors contribute t%li%the increasing prevalence of asthma. Exposure t%li%various environmental triggers such as allergens, air pollution, and tobacc%li%smoke can increase the risk of asthma. Urbanization and industrialization have led t%li%increased exposure t%li%these triggers in many parts of the world. A family history of asthma or allergic conditions can predispose individuals t%li%the development of asthma. Genetic factors play a significant role in susceptibility t%li%the disease.
Sedentary lifestyles, changes in dietary habits, and increased stress levels have been linked t%li%the rising prevalence of asthma. These factors can lead t%li%obesity, which is a known risk factor for asthma. Improved diagnostic methods and increased awareness about asthma have led t%li%more individuals seeking medical help, resulting in a higher number of reported cases. As the global population continues t%li%age, the prevalence of chronic diseases like asthma als%li%increases, as the condition is not limited t%li%any specific age group. Developing countries are witnessing a rise in asthma cases due t%li%urbanization and industrial growth, leading t%li%increased exposure t%li%asthma triggers. The increasing prevalence of asthma has driven the growth of the global asthma therapeutics market. Pharmaceutical companies have been investing in research and development t%li%create more effective treatments for asthma. The market includes a wide range of therapeutics, including inhaled corticosteroids, long-acting beta-agonists, leukotriene modifiers, and monoclonal antibodies, among others.
Increasing Healthcare Expenditure
Asthma is a chronic respiratory condition that affects millions of people worldwide. With a rising prevalence of asthma and an increasing focus on healthcare, the global asthma therapeutics market is experiencing significant growth. One of the primary drivers of this growth is the increasing healthcare expenditure in various countries. As governments and healthcare organizations recognize the growing burden of chronic diseases like asthma, they are allocating larger budgets t%li%healthcare. Increased healthcare expenditure is enabling better access t%li%healthcare services, including improved diagnosis and management of asthma. These investments have a direct impact on the asthma therapeutics market, driving its growth. Asthma therapeutics have come a long way in recent years, thanks t%li%advancements in medical research and technology. Pharmaceutical companies are investing heavily in the development of innovative drugs and therapies t%li%improve asthma management. With greater healthcare spending, more resources are available for research and development, leading t%li%the creation of more effective and efficient asthma treatments.
In many countries, the accessibility of asthma medications has improved significantly due t%li%increased healthcare expenditure. This means that patients have better access t%li%a wide range of asthma therapeutics, from quick-relief inhalers t%li%long-term control medications. This improved access ensures that patients can manage their condition effectively, leading t%li%better health outcomes. Higher healthcare spending als%li%allows for increased asthma awareness campaigns and patient education programs. When patients are well-informed about their condition and treatment options, they are more likely t%li%adhere t%li%their treatment plans. This ultimately leads t%li%better control of asthma, reducing the severity and frequency of symptoms and hospital admissions.
Research and development in the asthma therapeutics market are heavily influenced by healthcare expenditure. Greater financial support for research activities results in the discovery of new drugs and therapies that can revolutionize asthma management. These advancements benefit both patients and the pharmaceutical industry, as they create a more competitive and dynamic market. The global asthma therapeutics market is expanding as healthcare expenditure rises. In addition t%li%the core treatment options, there is a growing interest in personalized medicine and biologics in the treatment of asthma. These innovative approaches offer a promising future for patients with severe or difficult-to-treat asthma.
While increasing healthcare expenditure is driving growth in the asthma therapeutics market, there are some challenges t%li%address. Balancing the need for better treatments with the rising cost of healthcare is a delicate task. It's essential t%li%ensure that healthcare resources are utilized efficiently and that affordable treatment options are available t%li%all, regardless of socioeconomic status.
Key Market Challenges
Generic Competition
The patent expirations of several blockbuster asthma drugs have led t%li%increased competition from generic alternatives. While this can drive down prices, it can als%li%pose a challenge for pharmaceutical companies and innovators in terms of sustaining profitability and investing in research and development for new, innovative therapies. Asthma is a heterogeneous disease with various phenotypes and endotypes. Developing therapeutics that cater t%li%the diverse needs of patients is a complex task. Tailoring treatments t%li%individual asthma subtypes is challenging, as it requires a deep understanding of the underlying mechanisms and can be costly. Asthma management relies on long-term adherence t%li%medication regimens. However, many patients struggle with non-adherence, whether due t%li%inconvenience, side effects, or lack of understanding of the importance of consistent treatment. This can hinder the effectiveness of asthma therapeutics and result in uncontrolled asthma.
Key Market Trends
Technological Advancements
Asthma is a chronic respiratory condition that affects millions of people worldwide, causing symptoms such as wheezing, shortness of breath, and coughing. With the increasing prevalence of asthma cases globally, the demand for effective and innovative asthma therapeutics is on the rise. Technological advancements have played a pivotal role in the development of new and improved treatments, leading t%li%a booming Global Asthma Therapeutics Market. Technological innovations have led t%li%more accurate and efficient methods for diagnosing asthma. Traditional diagnostic methods, such as spirometry and peak flow measurements, have been supplemented with advanced diagnostic tools like exhaled nitric oxide (FeNO) testing and fractional exhaled nitric oxide (FeNO) monitors. These tools offer better insights int%li%airway inflammation, aiding in more precise asthma diagnosis. Telemedicine has revolutionized the healthcare industry, providing convenient access t%li%healthcare professionals and specialists. Remote monitoring devices, including smart inhalers and wearable sensors, allow patients and doctors t%li%track asthma symptoms and medication adherence. This real-time data helps in creating personalized treatment plans and ensures better management of the condition.
Advancements in genetic research and personalized medicine have allowed for the development of targeted asthma treatments. By identifying specific genetic markers associated with asthma, pharmaceutical companies can create therapies tailored t%li%an individual's unique genetic profile. This approach leads t%li%more effective treatments and fewer side effects. Biologics, a class of medications derived from living organisms, have emerged as a groundbreaking treatment for severe asthma. These drugs target specific molecules in the immune system, effectively reducing inflammation and preventing asthma exacerbations. Monoclonal antibodies, a type of biologic, are increasingly used t%li%treat severe asthma, offering hope t%li%patients wh%li%d%li%not respond well t%li%traditional therapies. Inhalers have come a long way with technological advancements. Smart inhalers, equipped with Bluetooth connectivity and companion mobile apps, help patients track their inhaler usage, monitor medication adherence, and receive reminders for inhalation. These innovations enhance patient engagement and contribute t%li%better asthma management.
AI and machine learning are invaluable tools in asthma research. They analyze vast amounts of patient data, identify patterns, and predict asthma exacerbations. Researchers use AI t%li%develop predictive models that can guide treatment decisions and improve patient outcomes. Advanced computational modeling and virtual screening techniques are accelerating the drug discovery process. These technologies help identify potential asthma therapies faster, reducing the time and costs associated with bringing new medications t%li%market. As a result, the pipeline for asthma drug candidates is growing rapidly.
Segmental Insights
Drug Class Insights
Based on drug class, Combination Therapy emerged as the fastest growing segment in the global market for asthma therapeutics in 2023. Combination therapy can provide better symptom control by addressing multiple aspects of asthma simultaneously. By combining a long-acting beta-agonist (LABA) with an ICS, for instance, patients can experience improved lung function, reduced inflammation, and fewer exacerbations. Asthma is not a one-size-fits-all condition. Combination therapy allows for personalized treatment regimens that can be adjusted t%li%suit an individual's specific needs, considering factors like the severity of their asthma, their response t%li%different medications, and comorbid conditions. Traditional reliance on SABA medications may lead t%li%overuse and increased risk of side effects. Combination therapy can reduce the need for SABA, promoting safer, more effective asthma management. Asthma exacerbations can be severe and sometimes life-threatening. Combination therapy can significantly reduce the risk of exacerbations, leading t%li%better long-term outcomes for asthma patients. With the development of advanced inhaler devices, patients can now conveniently administer combination therapies, making them easier t%li%incorporate int%li%their daily routines.
Product Insights
Based on product, the inhalers is projected t%li%experience rapid growth in the global asthma therapeutics market during the forecast period. Inhalers deliver medication directly t%li%the airways, ensuring that the drugs act where they are needed most. This targeted delivery reduces the risk of systemic side effects and provides faster relief. Inhalers are user-friendly and offer an easy, convenient method of medication administration. This enhances patient compliance, as individuals are more likely t%li%adhere t%li%their prescribed treatment plans. Inhalers typically require lower medication doses compared t%li%oral medications. This can lead t%li%cost savings for patients and healthcare systems and decrease the potential for adverse reactions. Inhalers come in various types, including short-acting and long-acting bronchodilators, inhaled corticosteroids, and combination therapies. This allows healthcare providers t%li%tailor treatment regimens t%li%the individual needs of asthma patients.
Regional Insights
Based on region, North America emerged as the dominant region in the Global Asthma Therapeutics Market in 2023, holding the largest market share in terms of value. One of the primary reasons for North America's leading position in the global asthma therapeutics market is the high prevalence of asthma in the region. The United States, Canada, and Mexic%li%collectively have a substantial population suffering from asthma, which drives the demand for effective asthma treatments and medications. As a result, pharmaceutical companies are heavily invested in the North American market, leading t%li%a robust pipeline of asthma therapeutics. North America boasts a sophisticated healthcare infrastructure, characterized by state-of-the-art medical facilities, a well-trained healthcare workforce, and a strong emphasis on research and development. This conducive environment has allowed the region t%li%excel in asthma research, enabling the development of innovative therapies and treatments. The presence of top-tier research institutions and pharmaceutical companies in North America has further contributed t%li%the region's dominance in the asthma therapeutics market.
Key Market Players
- Teva Pharmaceutical Industries Ltd.
- GSK plc.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca plc.
- Boehringer Ingelheim International GmbH
- Sanofi S.A.
- Koninklijke Philips N.V.
- Becton, Dickinson and Company
- Sunovion Pharmaceuticals, Inc.
In this report, the Global Asthma Therapeutics Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
- Asthma Therapeutics Market, By Drug Class:
- Anti-inflammatory
- Combination Therapy
- Bronchodilators
- Asthma Therapeutics Market, By Product:
- Inhalers
- Nebulizers
- Asthma Therapeutics Market, By Route of Administration:
- Oral
- Inhaled
- Others
- Asthma Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Asthma Therapeutics Market.
Available Customizations:
Global Asthma Therapeutics Market report with the given market data, Tech Sci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up t%li%five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. GLOBAL ASTHMA THERAPEUTICS MARKET OUTLOOK
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators)
4.2.2. By Product (Inhalers (Dry powder inhalers, Metered dose inhalers, Soft mist inhalers), Nebulizers)
4.2.3. By Route of Administration (Oral, Inhaled, Others)
4.2.4. By Region
4.2.5. By Company (2023)
4.3. Market Map
4.3.1. By Drug Class
4.3.2. By Product
4.3.3. By Route of Administration
4.3.4. By Region
5. ASIA PACIFIC ASTHMA THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class
5.2.2. By Product
5.2.3. By Route of Administration
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Asthma Therapeutics Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Drug Class
5.3.1.2.2. By Product
5.3.1.2.3. By Route of Administration
5.3.2. India Asthma Therapeutics Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Drug Class
5.3.2.2.2. By Product
5.3.2.2.3. By Route of Administration
5.3.3. Australia Asthma Therapeutics Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Drug Class
5.3.3.2.2. By Product
5.3.3.2.3. By Route of Administration
5.3.4. Japan Asthma Therapeutics Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Drug Class
5.3.4.2.2. By Product
5.3.4.2.3. By Route of Administration
5.3.5. South Korea Asthma Therapeutics Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Drug Class
5.3.5.2.2. By Product
5.3.5.2.3. By Route of Administration
6. EUROPE ASTHMA THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Product
6.2.3. By Route of Administration
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Asthma Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Product
6.3.1.2.3. By Route of Administration
6.3.2. Germany Asthma Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Product
6.3.2.2.3. By Route of Administration
6.3.3. Spain Asthma Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Product
6.3.3.2.3. By Route of Administration
6.3.4. Italy Asthma Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Drug Class
6.3.4.2.2. By Product
6.3.4.2.3. By Route of Administration
6.3.5. United Kingdom Asthma Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Drug Class
6.3.5.2.2. By Product
6.3.5.2.3. By Route of Administration
7. NORTH AMERICA ASTHMA THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Product
7.2.3. By Route of Administration
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Asthma Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Product
7.3.1.2.3. By Route of Administration
7.3.2. Mexico Asthma Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Product
7.3.2.2.3. By Route of Administration
7.3.3. Canada Asthma Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Product
7.3.3.2.3. By Route of Administration
8. SOUTH AMERICA ASTHMA THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Product
8.2.3. By Route of Administration
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Asthma Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Product
8.3.1.2.3. By Route of Administration
8.3.2. Argentina Asthma Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Product
8.3.2.2.3. By Route of Administration
8.3.3. Colombia Asthma Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Product
8.3.3.2.3. By Route of Administration
9. MIDDLE EAST AND AFRICA ASTHMA THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Product
9.2.3. By Route of Administration
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Asthma Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Product
9.3.1.2.3. By Route of Administration
9.3.2. Saudi Arabia Asthma Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Product
9.3.2.2.3. By Route of Administration
9.3.3. UAE Asthma Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Product
9.3.3.2.3. By Route of Administration
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. GLOBAL ASTHMA THERAPEUTICS MARKET: SWOT ANALYSIS
13. PORTER’S FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. COMPETITIVE LANDSCAPE
14.1. Teva Pharmaceutical Industries Ltd.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Product & Services
14.1.4. Financials (In case of listed)
14.1.5. Recent Developments
14.1.6. SWOT Analysis
14.2. GSK plc.
14.3. Merck & Co., Inc.
14.4. F. Hoffmann-La Roche Ltd.
14.5. AstraZeneca plc.
14.6. Boehringer Ingelheim International GmbH
14.7. Sanofi S.A.
14.8. Koninklijke Philips N.V.
14.9. Becton, Dickinson and Company
14.10. Sunovion Pharmaceuticals, Inc.
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. GLOBAL ASTHMA THERAPEUTICS MARKET OUTLOOK
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators)
4.2.2. By Product (Inhalers (Dry powder inhalers, Metered dose inhalers, Soft mist inhalers), Nebulizers)
4.2.3. By Route of Administration (Oral, Inhaled, Others)
4.2.4. By Region
4.2.5. By Company (2023)
4.3. Market Map
4.3.1. By Drug Class
4.3.2. By Product
4.3.3. By Route of Administration
4.3.4. By Region
5. ASIA PACIFIC ASTHMA THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class
5.2.2. By Product
5.2.3. By Route of Administration
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Asthma Therapeutics Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Drug Class
5.3.1.2.2. By Product
5.3.1.2.3. By Route of Administration
5.3.2. India Asthma Therapeutics Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Drug Class
5.3.2.2.2. By Product
5.3.2.2.3. By Route of Administration
5.3.3. Australia Asthma Therapeutics Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Drug Class
5.3.3.2.2. By Product
5.3.3.2.3. By Route of Administration
5.3.4. Japan Asthma Therapeutics Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Drug Class
5.3.4.2.2. By Product
5.3.4.2.3. By Route of Administration
5.3.5. South Korea Asthma Therapeutics Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Drug Class
5.3.5.2.2. By Product
5.3.5.2.3. By Route of Administration
6. EUROPE ASTHMA THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Product
6.2.3. By Route of Administration
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Asthma Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Product
6.3.1.2.3. By Route of Administration
6.3.2. Germany Asthma Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Product
6.3.2.2.3. By Route of Administration
6.3.3. Spain Asthma Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Product
6.3.3.2.3. By Route of Administration
6.3.4. Italy Asthma Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Drug Class
6.3.4.2.2. By Product
6.3.4.2.3. By Route of Administration
6.3.5. United Kingdom Asthma Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Drug Class
6.3.5.2.2. By Product
6.3.5.2.3. By Route of Administration
7. NORTH AMERICA ASTHMA THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Product
7.2.3. By Route of Administration
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Asthma Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Product
7.3.1.2.3. By Route of Administration
7.3.2. Mexico Asthma Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Product
7.3.2.2.3. By Route of Administration
7.3.3. Canada Asthma Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Product
7.3.3.2.3. By Route of Administration
8. SOUTH AMERICA ASTHMA THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Product
8.2.3. By Route of Administration
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Asthma Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Product
8.3.1.2.3. By Route of Administration
8.3.2. Argentina Asthma Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Product
8.3.2.2.3. By Route of Administration
8.3.3. Colombia Asthma Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Product
8.3.3.2.3. By Route of Administration
9. MIDDLE EAST AND AFRICA ASTHMA THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Product
9.2.3. By Route of Administration
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Asthma Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Product
9.3.1.2.3. By Route of Administration
9.3.2. Saudi Arabia Asthma Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Product
9.3.2.2.3. By Route of Administration
9.3.3. UAE Asthma Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Product
9.3.3.2.3. By Route of Administration
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. GLOBAL ASTHMA THERAPEUTICS MARKET: SWOT ANALYSIS
13. PORTER’S FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. COMPETITIVE LANDSCAPE
14.1. Teva Pharmaceutical Industries Ltd.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Product & Services
14.1.4. Financials (In case of listed)
14.1.5. Recent Developments
14.1.6. SWOT Analysis
14.2. GSK plc.
14.3. Merck & Co., Inc.
14.4. F. Hoffmann-La Roche Ltd.
14.5. AstraZeneca plc.
14.6. Boehringer Ingelheim International GmbH
14.7. Sanofi S.A.
14.8. Koninklijke Philips N.V.
14.9. Becton, Dickinson and Company
14.10. Sunovion Pharmaceuticals, Inc.
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
